Cross-cultural validation of the Decisional Conflict Scale in a sample of French patients

Mancini, Julien; Santin, Gaëlle; Chabal, Françoise; Julian‐Reynier, Claire

doi:10.1007/s11136-005-6003-9

Cited by 26 publications

(31 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, reliability was lower than expected on two subscales (feeling uniformed, Cronbach-a = 0.621; feeling unsupported, Cronbacha = 0.554). When these two subscales were combined based on a prior factor analysis, 30 the resulting Cronbach-alevels were improved (total decisional conflict, Cronbacha = 0.839; feeling uncertain, Cronbach-a = 0.884; feeling unclear about values, Cronbach-a = 0.728); and feeling uninformed and unsupported, Cronbach-a = 0.720).…”

Section: Discussionmentioning

confidence: 99%

Mammography Decision Aid Reduces Decisional Conflict for Women in Their Forties Considering Screening

Eden

Scariati

Klein

et al. 2015

Journal of Women's Health

View full text Add to dashboard Cite

Background: Clinical guidelines recommend a personalized approach to mammography screening for women in their forties; however, methods to do so are lacking. An evidence-based mammography screening decision aid was developed as an electronic mobile application and evaluated in a before-after study. Methods: The decision aid (Mammopad) included modules on breast cancer, mammography, risk assessment, and priority setting about screening. Women aged 40-49 years who were patients of rural primary care clinics, had no major risk factors for breast cancer, and no mammography during the previous year were invited to use the decision aid. Twenty women participated in pretesting of the decision aid and 75 additional women completed the before-after study. The primary outcome was decisional conflict measured before and after using Mammopad. Secondary outcomes included decision self-efficacy and intention to begin or continue mammography screening. Differences comparing measures before versus after use were determined using Wilcoxon signed rank tests. Results: After using Mammopad, women reported reduced decisional conflict based on mean Decisional Conflict Scale scores overall (46.33 versus 8.33; Z = -7.225; p < 0.001) and on all subscales ( p < 0.001). Women also reported increased mean Decision Self-Efficacy Scale scores (79.67 versus 95.73; Z = 6.816, p < 0.001). Although 19% of women changed their screening intentions, this was not statistically significant. Conclusions: Women reported less conflict about their decisions for mammography screening, and felt more confident to make decisions after using Mammopad. This approach may help guide women through the decision making process to determine personalized screening choices that are appropriate for them.

show abstract

Section: Discussionmentioning

confidence: 99%

Mammography Decision Aid Reduces Decisional Conflict for Women in Their Forties Considering Screening

Eden

Scariati

Klein

et al. 2015

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…The possible existence of a decisional conflict about joining the SA02 study was assessed using O'Connor's 16-item (each involving a 5-point Likert scale) decisional conflict scale [27] validated in French [28]. This scale yields a global score (range = 1-5; Cronbach's α = 0.91) as well as subscores (in the same range) on the following 5 subscales, corresponding to specific dimensions of decisional conflicts: Uncertainty subscale (confidence about the decision), Informed subscale (awareness of options), Values clarity subscale (attitudes to benefits and risks), Support subscale (receiving support, advice or pressure from other people), and Effective decision subscale (satisfaction with the decision).…”

Section: Methodsmentioning

confidence: 99%

Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy

Seror

Marino²,

Bertucci

et al. 2013

Public Health Genomics

View full text Add to dashboard Cite

Background/Aims: Incorporating gene expression profiling into routine clinical practices is beginning to be recommended as part of breast cancer treatment. The aim of the present study was to investigate the decision-making involved in genomic testing from the perspective of patients enrolled in a genomics-based clinical trial of adjuvant chemotherapy. Methods: The prospective SA02 clinical trial was designed to assess the clinical benefits of a genomic test on axillary lymph node-positive (N+) early breast cancer patients. The patients enrolled in the SA02 trial were defined by ‘good prognosis' genomic test results consistent with the delivery of postoperative anthracycline-based chemotherapy without taxane. The present companion study was presented by oncologists to 64 out of the 88 patients enrolled. Data were collected using self-administered questionnaires. Results: The response rate was 67% (questionnaires were returned 35 days on average after enrolment in the trial). Only 33% of the respondents accurately recalled or described their genomic test results. Although most N+ patients classically undergo anthracycline/taxane adjuvant chemotherapy, 23% of the present respondents did not recall participating in the clinical study involving chemotherapy without taxanes. Recall was mainly associated with higher risk perception of chemotherapy-related side effects and better understanding of test results. Among the respondents who recalled participating in the trial, 39% experienced decisional conflicts. Conclusions: Devoting greater efforts to explaining genomic test results to patients could be highly relevant in terms of the trade-off between the risk of unnecessary chemotherapy-related side effects and the loss of survival time possibly resulting from less aggressive treatment.

show abstract

“…Negative statements are reversed scored, with high scores indicating higher decision conflict. The DCS has previously been used in oncology settings to assess decisional conflict in patients with cancer, and reliability estimates have ranged between .75 and .97 (Dolan & Frisina, 2002;Koedoot et al, 2001;Mancini, Santin, Chabal, & Julian-Reynier, 2006). Construct validity was tested by comparing DCS scores with decisions to accept, reject, or delay a decision to participate in cancer screening, as well as knowledge about the risks of breast cancer.…”

Section: Treatment Decision Making: Decisional Outcomesmentioning

confidence: 99%

Decision Making and Distress Among Individuals Diagnosed with Follicular Lymphoma

Poe¹,

Hayslip²,

Studts³

2012

Journal of Psychosocial Oncology

View full text Add to dashboard Cite

Follicular lymphoma (FL) is an indolent lymphoma that generally responds well to treatment. However, individuals with FL commonly face multiple complex treatment decision-making (TDM) experiences because it frequently follows a relapsing and remitting course. This study explored TDM and distress among individuals with FL (N = 32). Results indicated that most participants reported little decisional conflict or regret and wanted to be actively involved in TDM. However, more than 25% of participants reported clinically-relevant cancer-specific distress, and 60% indicated moderate or higher anxiety symptoms. Research is needed to clarify the cause and course of the psychological distress revealed in this study.

show abstract

Cross-cultural validation of the Decisional Conflict Scale in a sample of French patients

Abstract: The French version of the DCS was found to give a reliable overall score. However, special care should be taken when using the individual subscores. In addition, it is necessary to take into account the context in which the decision-making occurs.

Cited by 26 publications

References 7 publications

Mammography Decision Aid Reduces Decisional Conflict for Women in Their Forties Considering Screening

Mammography Decision Aid Reduces Decisional Conflict for Women in Their Forties Considering Screening

Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy

Decision Making and Distress Among Individuals Diagnosed with Follicular Lymphoma

Contact Info

Product

Resources

About